researcher comment: cabazitaxel a new third-line option in mcrpc | ronald de wit
Published 4 years ago • 286 plays • Length 3:59
Download video MP4
Download video MP3
Similar videos
-
7:14
3-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer | amit bahl
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
0:34
discussing the safety profile of cabazitaxel in mcrpc
-
1:53
nicholas vogelzang, md, explains how cabazitaxel should be used in various lines of treatment in mpc
-
3:02
expert comment: the card trial | silke gillessen
-
7:50
importance of psa results (part 2) | usapang pangkalusugan
-
15:27
how does prostate cancer chemotherapy work? | prolonged survival & improved cure rates | pcri
-
7:13
website 2022 urologist: making the diagnosis
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
0:42
oliver sartor, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
3:47
cabazitaxel safe and effective in mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:37
cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
-
1:32
anis hamid, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
0:47
tanya dorff, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
4:25
researcher comment: the therap trial | michael hofman
-
0:58
andrew armstrong, md, on impressions of the card study investigating cabazitaxel in mcrpc patients
-
1:01
rana mckay, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
7:09
cabazitaxel use in metastatic prostate cancer
-
9:41
jevtana® (cabazitaxel) mechanism of action
-
7:13
how is prostate cancer detected? | urochannel
Clip.africa.com - Privacy-policy